Recruitment complete for Clarity's PROPELLER prostate cancer diagnostic trial

/PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the...

Related Keywords

Australia ,United States ,Sydney ,New South Wales ,American ,Alan Taylor ,Louise Emmett ,Clarity Pharmaceuticals ,National Cancer Institute ,Technology Platform ,Prnewswire Clarity Pharmaceuticals ,Cancer Statistics Center ,American Cancer Society ,Lead Principal Investigator ,Prof Louise Emmett ,Targeted Copper Theranostics ,Executive Chairman ,Phasei Positron Emission Tomography ,Targeted Copper Theranostic ,Cancer Statistics ,Mortality Worldwide ,Cancer Society ,